8-K: LifeStance Health Board Shake-up: New Directors Appointed
Director Changes
LifeStance Health Group announces immediate resignation of director Jeffrey Rhodes and appoints three new board members, Thurman Justice, Lori Goltermann, and Safwan Shabab.
Summary
- LifeStance Health Group, Inc. reported a change in its Board of Directors.
- Jeffrey Rhodes resigned from the Board and its committees, effective immediately on July 2, 2026.
- The resignation was not due to any disagreements with the Company.
- In response to the vacancy, the Board appointed Thurman Justice, Lori Goltermann, and Safwan Shabab as directors on July 2, 2026.
- Thurman Justice and Lori Goltermann were appointed as Class II directors, serving until the 2029 annual meeting.
- Safwan Shabab was appointed as a Class III director, serving until the 2027 annual meeting.
- Mr. Justice will join the audit and quality and compliance committees.
- Ms. Goltermann will join the compensation and nominating and governance committees.
- Mr. Shabab will join the nomination and governance committee.
- Mr. Justice and Ms. Goltermann each received an award of 35,492 restricted stock units under the 2021 Equity Incentive Plan, subject to continued service.
- Mr. Shabab's appointment is in accordance with a Stockholders Agreement dated June 9, 2021.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While board changes can introduce new perspectives, the immediate impact on financial performance is not evident from this filing alone.
Positives
- Addition of three new directors with specific committee assignments, potentially bringing fresh perspectives and expertise.
- New directors Thurman Justice and Lori Goltermann received restricted stock units, aligning their interests with long-term shareholder value.
- The resignation of Jeffrey Rhodes was not due to any disagreement, indicating a smooth transition.
Negatives
- Departure of a board member, Jeffrey Rhodes, which could lead to a temporary disruption or loss of institutional knowledge.
Risks
- Potential for initial integration challenges with new board members.
- The effectiveness of the new directors in their respective committees and overall board contribution remains to be seen.
Future Outlook
No specific future outlook or guidance was provided in this filing, which solely concerns board composition changes.
Management Comments
- The resignation of Mr. Rhodes is not a result of any disagreement between Mr. Rhodes and the Company.
Industry Context
StockSavvy.ai notes that board composition changes are common in the healthcare services sector, particularly for companies undergoing growth or strategic realignments. The appointment of directors with specific committee experience, such as audit, compensation, and governance, is a standard practice to ensure robust oversight.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Jeffrey Rhodes | Thurman Justice | 2026-07-02 | Resignation of previous director and to fill vacancy. |
| Director | Jeffrey Rhodes | Lori Goltermann | 2026-07-02 | Resignation of previous director and to fill vacancy. |
| Director | Jeffrey Rhodes | Safwan Shabab | 2026-07-02 | Resignation of previous director and to fill vacancy. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Committee Membership | Thurman Justice appointed to Audit Committee and Quality and Compliance Committee. | 2026-07-02 | Strengthens oversight in financial reporting and quality control. |
| Board Committee Membership | Lori Goltermann appointed to Compensation Committee and Nominating and Governance Committee. | 2026-07-02 | Enhances focus on executive compensation and board structure. |
| Board Committee Membership | Safwan Shabab appointed to Nomination and Governance Committee. | 2026-07-02 | Contributes to board composition and governance strategy. |
| Director Appointment | Appointment of Thurman Justice and Lori Goltermann as Class II directors until the 2029 annual meeting. | 2026-07-02 | Provides stability and continuity for a significant term. |
| Director Appointment | Appointment of Safwan Shabab as a Class III director until the 2027 annual meeting. | 2026-07-02 | Fills a board seat with a defined term. |
Related Party Transactions
- Safwan Shabab's appointment is pursuant to a Stockholders Agreement dated June 9, 2021, between the Company and certain of its stockholders, indicating a pre-existing relationship or agreement.
Stakeholder Impact
- Shareholders: Potential for improved board oversight and strategic direction with new members. The restricted stock units for new directors align their interests with shareholders.
- Employees: Indirect impact through potential changes in strategic direction or governance practices.
- Creditors: No immediate impact indicated, as the filing does not concern financial distress or restructuring.
Next Steps
- New directors Thurman Justice, Lori Goltermann, and Safwan Shabab will commence their duties on the Board and respective committees.
- Restricted stock units awarded to Mr. Justice and Ms. Goltermann will vest according to the terms of their agreements.
Key Dates
| Date | Description |
|---|---|
| 2021-06-09 | Date of Stockholders Agreement between the Company and certain of its stockholders. |
| 2021-06-15 | Date of filing of Exhibit 10.2 (Stockholders Agreement) to the Company's Current Report on Form 8-K. |
| 2026-07-02 | Effective date of Jeffrey Rhodes' resignation from the Board; Date of appointment of Thurman Justice, Lori Goltermann, and Safwan Shabab to the Board. |
| 2026-07-07 | Date of the Form 8-K filing. |
| 2027-01-01 | Approximate initial term end date for Class III director Safwan Shabab. |
| 2029-01-01 | Approximate initial term end date for Class II directors Thurman Justice and Lori Goltermann. |
Keywords
LifeStance Health, Board of Directors, Director Resignation, Director Appointment, Corporate Governance, Restricted Stock Units, SEC Filing, Form 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.